This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, H. Articles by Von Hoff, D. D. Search for Related Content PubMed PubMed Citation Articles by Wang, H. Articles by Von Hoff, D. D.

Identification of an Agent Selectively Targeting DPC4 (Deleted in Pancreatic Cancer Locus 4)–Deficient Pancreatic Cancer Cells

The Translational Genomics Research Institute, Phoenix, Arizona

Requests for reprints: Hong Wang, Pancreatic Cancer Research Laboratory, Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, AZ 85004. Phone: 602-343-8742; Fax: 602-343-8740; E-mail: hwang{at}tgen.org.

One of the most common types of genetic alterations in cancer is the loss-of-function mutations in tumor-suppressor genes. Such mutations are usually very specific to cancer cells and present attractive and unique opportunities for therapeutic interventions. However, for various reasons, antitumor agents that target loss-of-function mutations have not been readily identified. In this report, using the deleted in pancreatic cancer locus 4 (DPC4) gene in pancreatic cancer as an example, we show the feasibility of a novel screening strategy, which we have named Pharmacological Synthetic Lethal Screening, for the identification of agents that selectively target cancer cells with loss-of-function mutations. We created DPC4 isogenic cell lines through the restoration of wild-type DPC4 in a pancreatic cancer cell line, BxPC-3, whose DPC4 gene was homozygously deleted. The isogenic cell lines were then used in the Pharmacological Synthetic Lethal Screening to evaluate compound libraries for antiproliferative activity and selectivity against DPC4 deficiency. After screening 19,590 compounds, we identified one lead compound, UA62001, which showed 4.6-fold selectivity against DPC4 deficiency in the DPC4 isogenic cell lines. UA62001 selectivity was also seen in another set of DPC4 isogenic cell lines generated by small interfering RNA knockdown. In addition, UA62001 was evaluated in commonly used pancreatic cancer cell lines. A fairly good correlation between DPC4 deficiency and UA62001 sensitivity was observed. Cell cycle analysis indicates that UA62001 arrests cells in S and G₂-M phases. The results of microarray gene expression profiling and quantitative real-time reverse transcription-PCR suggest that cyclin B/CDC2 and minichromosome maintenance complexes might be the downstream cellular targets of UA62001. (Cancer Res 2006; 66(19): 9722-30)

This article has been cited by other articles:

				A. Y. Shaw, M. C. Henderson, G. Flynn, B. Samulitis, H. Han, S. P. Stratton, H.-H. S. Chow, L. H. Hurley, and R. T. Dorr Characterization of Novel Diaryl Oxazole-Based Compounds as Potential Agents to Treat Pancreatic Cancer J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 636 - 647. [Abstract] [Full Text] [PDF]

				M. C. Henderson, Y.-J. Y. Shaw, H. Wang, H. Han, L. H. Hurley, G. Flynn, R. T. Dorr, and D. D. Von Hoff UA62784, a novel inhibitor of centromere protein E kinesin-like protein Mol. Cancer Ther., January 1, 2009; 8(1): 36 - 44. [Abstract] [Full Text] [PDF]

				S. Turcotte and A. J. Giaccia Targeted Therapy for the Loss of the Tumor Suppressor Gene von Hippel-Lindau through Synthetic Lethality ASCO Educational Book, January 1, 2008; 2008(1): e15 - e18. [Abstract] [Full Text] [PDF]